BCR-ABL1 is a fusion gene usually formed via a t(9;22) (q34;q11) translocation (Faderl et al. 1999). This translocation results in the Philadelphia chromosome. In rare cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene. These sometimes involve multiple chromosomes.


BCR-ABL1 is present in all cases of chronic myeloid leukemia, but it is also involved in other cancers.  These include pediatric B-cell acute lymphoblastic leukemia (3-5%), adult B-cell acute lymphoblastic leukemia (25-30%), acute myeloid leukemia (rare), and T-cell acute lymphoblastic leukemia (rare; De Braekeleer et al. 2011).

ABL1 kinase inhibitors have been developed as targeted therapies against BCR-ABL1 positive malignancies.

Related Pathways

Contributors: Aaron Shaver, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S.

Suggested Citation: Shaver, A., Jagasia, M. 2015. BCR-ABL1. My Cancer Genome (Updated December 2015)

Modified: December 7, 2015

Disclaimer: The information presented at is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.